DR. JUAN A. OLIVER, M.D.
Osteopathic Medicine at 168 St, New York, NY
License number
New York 119602
Category
Osteopathic Medicine
Type
Internal Medicine
License number
New York 119602
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
622 W 168Th St, New York, NY 10032
Phone
(212) 305-6938
(212) 305-5016
(212) 305-5016
Personal information
See more information about JUAN A. OLIVER at radaris.comName
Address
Phone
840 Broadway APT 9, New York, NY 10003
493 Hart St, Brooklyn, NY 11221
41 Lucille Ln APT 8B, Deer Park, NY 11729
330 Bushwick Ave APT 4K, Brooklyn, NY 11206
22 Smith St, Port Chester, NY 10573
Organization information
See more information about JUAN A. OLIVER at bizstanding.comJuan Oliver MD
630 W 168 St, New York, NY 10032
Industry:
Internist
Site:
Phone:
(212) 305-3273 (Phone)
Description:
There are 21 doctors at this site. Surgery is not performed at this site.
Juan A. Oliver
Columbia University - Juan A Oliver MD
630 W 168 St #441, New York, NY 10032
Categories:
Internal Medicine Physicians & Surgeons, Nephrology Physicians & Surgeons
Phone:
(212) 305-6874 (Phone)
Professional information
Independent Business Owner At Self Employed
Position:
Independent Business Owner at Self Employed
Location:
Greater New York City Area
Industry:
Health, Wellness and Fitness
Work:
Self Employed
-
Independent Business Owner
Juan A Oliver, New York NY
Specialties:
Internal Medicine, Nephrology
Work:
Columbia University
630 W 168Th St, New York, NY 10032 Columbia Presbyterian Physicians Network
622 W 168Th St, New York, NY 10032
630 W 168Th St, New York, NY 10032 Columbia Presbyterian Physicians Network
622 W 168Th St, New York, NY 10032
Education:
Universidad De Barcelona (1967)
Independent Business Owner At Self Employed
Position:
Independent Business Owner at Self Employed
Location:
Greater New York City Area
Industry:
Health, Wellness and Fitness
Work:
Self Employed
-
Independent Business Owner
Dr. Juan A Oliver - MD (Doctor of Medicine)
Hospitals:
Columbia University Medical Center NEP
622 W 168Th St, New York 10032
Columbia University Medical Center NEP
622 W 168Th St, New York 10032
622 W 168Th St, New York 10032
Columbia University Medical Center NEP
622 W 168Th St, New York 10032
Education:
Medical Schools
Universidad Autonoma De Barcelona, Facultad De Medicina
Graduated: 1967
Universidad Autonoma De Barcelona, Facultad De Medicina
Graduated: 1967
Method Of Inducing Formation Of Kidney Epithelia From Mesenchymal Precursors
US Patent:
6423681, Jul 23, 2002
Filed:
May 4, 1999
Appl. No.:
09/305029
Inventors:
Jonathan M. Barasch - New York NY
Juan A. Oliver - New York NY
Jun Yang - New York NY
Juan A. Oliver - New York NY
Jun Yang - New York NY
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
A61K 3802
US Classification:
514 2, 514 21
Abstract:
This invention provides methods of using a gpl3O receptor ligand, e. g. leukemia inhibitory factor, to induce the formation of kidney epithelia, to treat subjects suffering from kidney failure, and to preserve kidneys for transplantation.
Real-Time Assays Of Neuro-Humoral Factors To Assess Cardiovascular Stress
US Patent:
2011006, Mar 17, 2011
Filed:
Apr 22, 2010
Appl. No.:
12/765607
Inventors:
Donald W. Landry - New York NY, US
Juan Oliver - New York NY, US
Milan N. Stojanovic - Fort Lee NJ, US
Juan Oliver - New York NY, US
Milan N. Stojanovic - Fort Lee NJ, US
International Classification:
C12Q 1/68, G01N 33/543
US Classification:
435 6, 436501
Abstract:
The present invention relates to rapid assays for neuro-humoral factors modulated in response to cardiovascular stress and integration of data obtained from such assays to provide profiles of response to cardiovascular stress that can guide therapy.
Real-Time Assays Of Neuro-Humoral Factors To Assess Cardiovascular Stress
US Patent:
2009000, Jan 1, 2009
Filed:
Jun 23, 2008
Appl. No.:
12/144160
Inventors:
Donald W. Landry - New York NY, US
Juan Oliver - New York NY, US
Milan N. Stojanovic - Fort Lee NJ, US
Juan Oliver - New York NY, US
Milan N. Stojanovic - Fort Lee NJ, US
International Classification:
C12Q 1/68, G01N 33/566
US Classification:
435 6, 436501
Abstract:
The present invention relates to rapid assays for neuro-humoral factors modulated in response to cardiovascular stress and integration of data obtained from such assays to provide profiles of response to cardiovascular stress that can guide therapy.
Method For Stabilizing Blood Pressure In Hemodialysis Subjects
US Patent:
2007021, Sep 13, 2007
Filed:
Feb 26, 2007
Appl. No.:
11/710754
Inventors:
Donald Landry - New York NY, US
Juan Oliver - New York NY, US
Juan Oliver - New York NY, US
International Classification:
A61K 38/08, A61K 31/00
US Classification:
514009000, 514001000, 514015000, 514016000
Abstract:
The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.
Method For Stabilizing Blood Pressure In Hemodialysis Subjects
US Patent:
7183255, Feb 27, 2007
Filed:
Feb 26, 2004
Appl. No.:
10/789548
Inventors:
Donald W. Landry - New York NY, US
Juan A. Oliver - New York NY, US
Juan A. Oliver - New York NY, US
Assignee:
Intradialytic Pharmaceuticals - Niagara Falls NY
International Classification:
A61K 38/17
US Classification:
514 12, 514 2, 530350
Abstract:
The present invention provides a method for regulating blood pressure in a hemodialysis subject using a vasopressin receptor agonist, so as to facilitate removal of excessive extracellular fluid in the subject.
Method Of Inducing Formation Of Kidney Epithelia From Mesenchymal Precursors
US Patent:
7022666, Apr 4, 2006
Filed:
May 4, 2000
Appl. No.:
09/980853
Inventors:
Jonathan M. Barasch - New York NY, US
Juan A. Oliver - New York NY, US
Jun Yang - New York NY, US
Juan A. Oliver - New York NY, US
Jun Yang - New York NY, US
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
A61K 38/18
US Classification:
514 2, 514 21
Abstract:
This invention provides methods of using a gp130 receptor ligand, e. g. leukemia inhibitory factor, to induce the formation of kidney epithelia, to treat subjects suffering from kidney failure, and to preserve kidneys for transplantation.